Kura Oncology Inc. (KURA)
NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KURA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $634.88M
- EPS (TTM)
- -$3.30
- Dividend yield
- None
- 52-week range
- 6.75 – 13.90
- Day range
- 6.89 – 7.37
- Volume / Avg
- 1.75M / 2.10M
- Beta
- —
- Shares outstanding
- 91.88M
52-week range
KURA stock today
On Nov 20, KURA ended the session at $6.91, shedding $0.44 (5.99%), versus the S&P 500's 3.70% decline. Shares are 50.3% below their 52-week high of $13.90, set on Aug 25, 2026 and 2.4% above the 52-week low of $6.75, near the bottom of the past year's range. KURA is down 33.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.1%.
Kura Oncology has posted a net loss over the last twelve months (EPS of -$3.30), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Kura Oncology
Company profileKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Troy Edward Wilson J.D., Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 260
- Website
- kuraoncology.com
Financial highlights
Full financialsIn fiscal 2025, Kura Oncology generated $67.5 million in revenue, up 25.2% from fiscal 2024, its 2nd consecutive year of revenue growth. Kura Oncology reported a net loss of $278.7 million, compared with a loss of $174.0 million a year earlier. Operating margin was -449.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $67.48M | $53.88M | $0 | — | — |
| Growth | +25.24% | — | — | — | — |
| Net income | $-278.67M | $-173.98M | $-152.63M | $-135.84M | $-130.47M |
| EPS (diluted) | $-3.18 | $-2.02 | $-2.08 | $-2.03 | $-1.97 |
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$31.62+357.60%
- Strong buy 3
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.85 vs $-0.83
- Surprise
- -2.41%
KURA news
All KURA news- Tuesday 11/17 Insider Buying Report: KURA, IONDNasdaqKURA, IOND
- Kura Oncology to Participate in Two Investor Conferences in NovemberGlobeNewswire
- Kura Oncology Reports Q3 Results; KOMZIFTI Revenue Grows 53%, Advances 2027 Pipeline PlansNasdaqKURA, BF.A
- Kura Oncology (KURA) Q3 2026 Earnings Call TranscriptNasdaq
- Kura Oncology GAAP EPS of -$0.78 beats by $0.05, revenue of $22.84M misses by $1.05MSeeking Alpha
- Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate UpdateGlobeNewswire
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026GlobeNewswire
Kura Oncology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SGMTSagimet Biosciences Inc. Series A | 9.08 | -5.61% | $648.02M | vs KURA |
| JANXJanux Therapeutics Inc. | 10.08 | -2.04% | $616.73M | vs KURA |
| ABUSArbutus Biopharma Corporation | 4.02 | -1.23% | $616.24M | vs KURA |
| OLMAOlema Oncology Inc. | 7.02 | -1.82% | $615.00M | vs KURA |
| NVCTNuvectis Pharma Inc. | 19.39 | -2.27% | $666.80M | vs KURA |
| APMDApnimed Inc. | 16.09 | -6.70% | $669.84M | vs KURA |
| ANNXAnnexon Inc. | 3.10 | -9.09% | $591.37M | vs KURA |
| LXRXLexicon Pharmaceuticals Inc. | 1.53 | -8.38% | $681.21M | vs KURA |
Indexes, lists and sector
Kura Oncology stock FAQ
What is Kura Oncology's stock price today?
KURA last traded at $6.91 as of Nov 20, 4:00 PM EST, down 5.99% on the day. Prices are delayed at least 15 minutes.
Who is Kura Oncology's CEO?
Dr. Troy Edward Wilson J.D., Ph.D. is the chief executive officer of Kura Oncology Inc., which has about 260 employees.
What is the KURA 52-week high?
The 52-week high for KURA is $13.90 and the 52-week low is $6.75. The stock is currently 50.3% below its high.